Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lung Neoplasms × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Ovarian Neoplasms 5 Neoplasm Metastasis 4 Advanced Solid Tumors 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Leukemia, Myeloid, Acute 3 Triple Negative Breast Neoplasms 2 Pancreatic Neoplasms 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Sarcoma, Ewing 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Neuroendocrine Tumors 1 Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Mesothelioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1

Interventions

Radiotherapy 33 pembrolizumab 32 Cisplatin 32 Carboplatin 31 Pemetrexed 23 Paclitaxel 22 Docetaxel 17 Specimen Handling 16 Magnetic Resonance Spectroscopy 16 Gemcitabine 16 Nivolumab 15 Cyclophosphamide 14 osimertinib 13 Bevacizumab 13 Irinotecan 12 Etoposide 12 Erlotinib Hydrochloride 12 durvalumab 11 Radiation 11 Cetuximab 9 Topotecan 8 Immunoglobulin G 8 Disulfides 8 Celecoxib 8 fludarabine 7 Radiosurgery 7 Fluorouracil 7 Everolimus 7 Biopsy 7 atezolizumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04170946 2026-03-05

Talazoparib

University Health Network, Toronto

Phase 1 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡